Clinical Trial Update: Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence trial comparing Eptacog Alfa A 6 mg to NovoSeven in healthy male subjects has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Bleeding Disorders
• Hemophilia

Drugs mentioned

• Eptacog Alfa A 6 mg (Eptacog alfa)
• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A | Phase 1 | Status: WITHDRAWN